Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE

Allergan and MAP Pharmaceuticals to Collaborate on Migraine Treatment

By Pharmaceutical Processing | February 1, 2011

Allergan, Inc. and MAP Pharmaceuticals, Inc. have announced a collaboration
within the United States
for LEVADEX(TM), a self-administered, orally inhaled therapy that has completed
Phase III clinical development for the treatment of acute migraine in adults.
MAP Pharmaceuticals currently anticipates submitting its New Drug Application
(NDA) for LEVADEX(TM) with the United States Food and Drug Administration (FDA)
in the first half of 2011.

LEVADEX(TM) contains a proprietary formulation of
dihydroergotamine (DHE), a drug delivered via IV, injection or nasal spray and
used in clinical practice today for the treatment of acute migraine. Utilizing MAP
Pharmaceuticals’ proprietary drug delivery system, the TEMPO(R) inhaler, the
unique formulation can be self-administered by the patient and is absorbed
through the lungs. If approved, LEVADEX(TM) may offer an easy to use, at-home
therapy option for acute migraine sufferers.

Under the terms of the collaboration, following potential
FDA approval of LEVADEX(TM), Allergan and MAP Pharmaceuticals will co-promote LEVADEX(TM)
to neurologists and pain specialists in the United States.

Specifically, Allergan will leverage its existing U.S. sales
force dedicated to headache specialists using BOTOX(R) for Chronic Migraine, which
will be complemented by MAP Pharmaceuticals’ field sales force targeting
neurologists and pain specialists. MAP Pharmaceuticals will retain all rights
to commercialize LEVADEX(TM) outside the United States,
as well as to primary care physicians within the United States.

 

Related Articles Read More >

This is a screenshot from a Varda Space Industries promotional video showing a space capsule with the company's logo docking onto a satellite.
Varda raises $187M Series C for drug manufacturing in space
This is the logo of Hikma.
Hikma to spend another $1B on US manufacturing, R&D
Great Point Partners logo.
Great Point Partners acquires majority stake in Eutecma to fuel sustainable cold chain growth
Driving success in fast-paced high-tech pharma construction projects
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertise
  • SUBSCRIBE